Plain Language Summary {#Sec1}
======================

Fatty acids are an important energy substrate, but specific fatty acids also play consequential and distinct roles in cellular function and in the development and progression of cardiovascular disease. Intake of omega-3 fatty (n-3) acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may differentially affect cardiovascular risk. Therefore, understanding the effects of specific fatty acid therapies on fatty acid profiles in plasma and red blood cells (RBCs) may provide insight into how given therapies may affect cardiovascular disease. We examined the effects of icosapent ethyl 4 g/day, a high-purity prescription form of EPA, versus a placebo on fatty acid levels in blood. Patients were treated with statins to control low-density lipoprotein cholesterol, but still had high triglycerides. Gas chromatography was used to measure omega-3, omega-6, saturated, and other fatty acid levels in plasma and RBCs. In plasma, icosapent ethyl 4 g/day increased EPA concentrations 635% and EPA's omega-3 metabolite docosapentaenoic acid (DPA) 143%, and decreased levels of the omega-6 fatty acid arachidonic acid (AA) 31%, the AA to EPA ratio 91%, and saturated fatty acid levels (stearic and palmitic acids) 16 and 23%, respectively (all comparisons statistically significant versus placebo), while DHA levels did not change. Trends were similar for RBCs, except DHA was reduced 6% and there were no changes in stearic or palmitic acids. Results provide insight into the potential cardiovascular benefits of icosapent ethyl 4 g/day and how they might be related to, or distinct from, changes in other fatty acid levels.

Introduction {#Sec2}
============

Fatty acid classes include saturated, monounsaturated, and polyunsaturated, such as omega-9, omega-6, and omega-3. Fatty acids are not only sources of energy but are also important physiologic modulators. The proportions and concentrations of various fatty acids in plasma and red blood cell (RBC) membranes are associated with cardiovascular risk and the production of inflammatory mediators \[[@CR1]--[@CR7]\], and substantial intake of omega-3 fatty acids may affect the fatty acid composition of plasma and RBC membranes \[[@CR1], [@CR4]\]. Studies of intervention with the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) suggest a variety of potential cardiovascular-related physiological benefits: they lower plasma triglyceride (TG) levels, improve other atherogenic lipid levels, and may have beneficial effects on inflammation, vascular function, resting heart rate, blood pressure, myocardial filling and efficiency, arrhythmia, plaque stabilization, and platelet aggregation \[[@CR7]--[@CR9]\]. Despite some similarities, there are also differences in EPA and DHA, such as an observed increase in low-density lipoprotein cholesterol (Ldl-C) in some patients administered DHA-containing omega-3 mixtures that is not observed with EPA-only therapy \[[@CR10]--[@CR12]\]. Analysis of fatty acid levels in plasma and RBCs may provide greater understanding of the potential physiologic effects of omega-3 fatty acid treatment on lipid levels \[[@CR13]\] and effects beyond lipids.

Icosapent ethyl (Vascepa; Amarin Pharma Inc, Bedminster, NJ, USA) is a high-purity prescription form of EPA ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce TG levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia \[[@CR14]\]. Compared with placebo in the 12-week, randomized, double-blind, placebo-controlled MARINE study (very high TG levels of 500--2000 mg/dl) and ANCHOR study (TG levels 200--499 mg/dl despite statin stabilization), icosapent ethyl significantly improved levels of TGs and other atherogenic lipid, lipoprotein, and inflammatory parameters without raising the levels of Ldl-C \[[@CR12], [@CR15]--[@CR19]\]. In these studies, icosapent ethyl was safe and generally well tolerated, with a safety profile similar to that of placebo \[[@CR12], [@CR14], [@CR17]\].

This analysis evaluated data from the ANCHOR study to determine the effects of icosapent ethyl at the approved dose of 4 g/day on fatty acid levels in plasma and RBCs in statin-treated patients with persistently high TGs.

Methods {#Sec3}
=======

This prespecified exploratory analysis evaluated fatty acid levels in plasma and RBC membranes in a subset of patients from the ANCHOR study. Details of the ANCHOR study were previously published \[[@CR17]\]. In brief, ANCHOR was a phase 3, multicenter, 12-week, double-blind, randomized, placebo-controlled study in patients at high risk for cardiovascular disease who had high TG levels while on stable statin therapy (with or without ezetimibe) to control Ldl-C levels. Patients aged \> 18 years entered a 4- to 6-week lead-in period of diet, lifestyle, and statin stabilization during which nonstatin lipid treatments were washed out. This lead-in period was followed by a 2- to 3-week lipid-qualifying period (fasting TGs: 200--499 mg/dl; fasting Ldl-C: 40--99 mg/dl). Eligible patients were randomized (1:1:1) to a 12-week double-blind treatment period with either icosapent ethyl 4 g/day, 2 g/day, or placebo; this report focuses on the FDA-approved dose of 4 g/day versus placebo. The protocol was approved by the appropriate institutional review boards and patients provided informed written consent prior to enrollment. All procedures performed in this study were in accordance with duly constituted Institutional Review Boards for each study center and with the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all individual participants included in the study.

As prespecified in the study protocol as exploratory efficacy parameters, the method used to measure and analyze fatty acid levels in plasma and RBCs from patients in the ANCHOR study is similar to that previously published \[[@CR13]\]. The method involved a validated gas chromatograph assay method with flame ionization detector (GC/FID; performed by Mylnefield Research Services Ltd, Scottish Crop Research Institute, Dundee, Scotland, UK). Briefly, fasting blood samples were collected prior to the administration of study drug at baseline and week 12. After centrifugation of the fasting blood samples, the plasma layer was removed for analysis. The buffy coat was removed from the remaining fraction and the RBCs were then washed with an equal volume of 0.9% saline or phosphate buffered saline. Following centrifugation, the saline wash was removed and the remaining RBC samples and the previously removed plasma samples were stored frozen at − 80 °C. Lipids were extracted from plasma and RBC suspensions and converted into fatty acid methyl esters for GC/FID analysis and determination of the fatty acid profile. The GC/FID assay measures total fatty acid concentrations including unesterified fatty acids and esterified fatty acids that are incorporated in circulating phospholipids, triacylglycerols, and cholesteryl esters. The lipid fraction was isolated by centrifugation after adding acid/methanol/chloroform. Lipid hydrolysis and transmethylation were accomplished with acid/methanol overnight at 50 °C, followed by extraction with chloroform/methanol and an acidified salt wash to remove non-lipid contaminants. Fatty acids were quantified with FID and the lower limit of quantitation was 3 μg/g in plasma and RBCs. Concentrations were expressed as micrograms of each fatty acid per gram of sample (μg/g) or as a proportion in mole percent (mol%), which is the molar concentration of each fatty acid expressed as a percentage of the total molar fatty acid concentration of four classes (saturated, monounsaturated, omega-3, and omega-6 fatty acids). Per study protocol, the prespecified exploratory fatty acid analysis was conducted in the first 72 patients with available complete sample sets. Samples from the other patients in the study were banked for later analysis per protocol. Of the banked samples, 85 were assayed subsequently, of which 83 had complete sample sets for a total of 155 patients included in the analysis (4 g/day, *n* = 50; 2 g/day, *n* = 52; placebo, *n* = 53). Outliers were identified and excluded for each fatty acid parameter for each treatment group. Outliers were defined as percent change values \< Q1 − 1.5 · IQR or \> Q3 + 1.5 · IQR, where Q1 and Q3 are first and third quartiles of the percent change values for the treatment group and IQR is the interquartile range (Q3--Q1). Because outliers were defined separately for each fatty acid measure, the numbers of subjects included for some parameters were different.

Statistical analyses were performed as previously defined \[[@CR13]\]. An analysis of covariance (ANCOVA) model with treatment, gender, type of statin therapy, and presence of diabetes at randomization as factors and the associated baseline value as a covariate for each fatty acid parameter was used for comparisons between icosapent ethyl and placebo groups. Summary statistics \[*n*, mean, and standard deviation (SD)\] were provided. For each treatment group and each comparison between icosapent ethyl and placebo groups, the least squares (LS) means and standard errors (SEs) were calculated. Linear contrasts of the ANCOVA model were used to obtain the LS estimates and *P* values for the comparisons of icosapent ethyl with placebo, with a significance level of *P *= 0.05. The statistical analyses for all fatty acids were considered as exploratory endpoints in the formal study statistical analysis plan.

Results {#Sec4}
=======

The ANCHOR trial randomized 702 statin-treated patients to icosapent ethyl 4 g/day, 2 g/day, or placebo. Reported here are fatty acid findings in patients receiving icosapent ethyl 4 g/day (*n* = 50) or placebo (*n* = 52) in the ANCHOR study with available fatty acid data. Baseline characteristics were similar between the two treatment groups in the randomized population \[[@CR17]\].

Key omega-3 fatty acids of interest included EPA (C20:5n-3), DHA (C22:6n-3), and docosapentaenoic acid (DPA, C22:5n-3; an EPA metabolite and precursor to DHA), the omega-6 fatty acid, arachidonic acid (AA, C20:4n-6), and the proportion of total omega-3, omega-6, monounsaturated, and saturated fatty acids to the total fatty acid pool measured.

Respective mean molar EPA plasma concentrations (mol% ± SD) in the icosapent ethyl and placebo groups were 0.4 ± 0.1% and 0.5 ± 0.6% at baseline and 3.6 ± 1.4% and 0.5 ± 0.5% at week 12, respectively. Icosapent ethyl 4 g/day produced significant mean percent increases in the plasma and RBC concentrations of EPA and its DPA metabolite and significant decreases in AA concentrations and the AA/EPA ratio (all *P *\< 0.0001; Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}) versus placebo. DHA concentrations did not change significantly in plasma, but showed a small significant (*P *\< 0.02) mean percent decrease with icosapent ethyl 4 g/day versus placebo in RBCs (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Change from baseline to week 12 in plasma concentrations of key fatty acidsPlasma fatty acid^a^IPE 4 g/dayPlaceboChange from baseline, IPE 4 g/day vs placebo, %, *P*Concentration, μg/gBaseline (SD)Week 12 (SD)Change (SE)Baseline (SD)Week 12 (SD)Change (SE)EPA (C20:5n-3)19.57144.68135.9824.2924.3910.43634.50*n* = 43, 51(6.410)(56.464)(5.998)(29.025)(25.073)(5.457)\< 0.0001DHA (C22:6n-3)51.8054.022.8458.5461.594.44− 1.12*n* = 48, 52(15.369)(13.842)(1.852)(34.274)(32.907)(1.743)0.7820DPA (C22:5n-3)20.1950.4531.7921.4123.833.91143.27*n* = 49, 52(5.573)(14.172)(1.794)(7.999)(9.403)(1.714)\< 0.0001Palmitic (C16:0)974.49846.22− 162.11038.71100.256.28− 22.87*n* = 48, 51(223.707)(213.932)(44.906)(299.038)(352.507)(42.832)\<0.0001Stearic (C18:0)278.90254.07− 30.83291.88304.5413.52− 16.16*n* = 50, 50(55.757)(48.217)(8.149)(61.887)(62.494)(7.995)\<0.0001Oleic (C18:1n-9)979.09784.41− 220.01011.01091.566.70− 29.48*n* = 47, 51(261.606)(208.940)(49.146)(296.705)(403.343)(46.802)\< 0.0001Linoleic (C18:2n-6)1069.4922.28− 152.51093.01221.8127.42− 24.75*n* = 50, 52(262.259)(200.324)(38.151)(258.966)(350.910)(36.433)\< 0.0001AA (C20:4n-6)282.84223.26− 60.69306.96328.1726.25− 30.87*n* = 50, 52(71.080)(65.530)(6.295)(74.556)(67.119)(6.124)\< 0.0001AA/EPA16.231.61− 14.1716.9716.630.60− 90.64*n* = 47, 50(6.665)(0.795)(0.556)(6.785)(6.638)(0.532)\< 0.0001^a^Patient numbers (*n*) are reported for IPE 4 g/day and placebo, respectivelyMean and SD are reported for baseline and end-of-treatment values; least squares means and SEs are reported for changes from baseline; least squares means are reported for percent changes from baseline vs. placebo*AA* arachidonic acid,*DHA* docosahexaenoic acid,*DPA* docosapentaenoic acid,*EPA* eicosapentaenoic acid,*IPE* icosapent ethyl,*SD* standard deviation,*SE* standard error Table 2Change from baseline to week 12 in red blood cell membrane concentrations of key fatty acidsRBC membrane fatty acid^a^IPE 4 g/dayPlaceboChange from baseline, IPE 4 g/day vs placebo, %, *P*Concentration, μg/gBaseline (SD)Week 12 (SD)Change (SE)Baseline (SD)Week 12 (SD)Change (SE)EPA (C20:5n-3)6.0943.2839.387.096.400.84618.46*n* = 49, 48(2.248)(17.957)(1.791)(3.320)(3.313)(1.730)\< 0.0001DHA (C22:6n-3)44.1039.14− 6.2947.3545.12− 2.70− 6.12*n* = 44, 47(11.708)(8.328)(0.983)(11.696)(11.861)(0.919)0.0178DPA (C22:5n-3)28.5462.1433.6729.6928.60− 0.85123.56*n* = 46, 46(5.757)(12.564)(1.417)(5.496)(5.146)(1.380)\< 0.0001Palmitic (C16:0)304.13301.24− 5.77313.71313.520.04− 2.24*n* = 46, 50(36.930)(36.607)(4.438)(39.421)(32.643)(4.151)0.1895Stearic (C18:0)170.95170.73− 1.15173.93174.730.74− 0.71*n* = 45, 46(18.926)(18.752)(2.550)(15.024)(18.323)(2.466)0.7048Oleic (C18:1n-9)194.52188.77− 7.74198.70198.42− 1.00− 3.15*n* = 45, 45(27.259)(23.798)(3.060)(24.650)(24.609)(2.997)0.0943Linoleic (C18:2n-6)146.81132.49− 15.77151.38153.501.53− 10.65*n* = 48, 48(31.853)(26.003)(3.752)(24.241)(32.521)(3.612)0.0004AA (C20:4n-6)185.38153.50− 37.08189.44193.570.98− 19.48*n* = 44, 47(37.044)(28.599)(3.596)(25.769)(27.707)(3.417)\< 0.0001AA/EPA31.863.61− 26.9531.4433.263.10− 98.64*n* = 46, 50(10.373)(1.700)(0.801)(11.465)(9.955)(0.767)\<0.0001^a^Patient numbers (*n*) are reported for IPE 4 g/day and placebo, respectivelyMean and SD are reported for baseline and end-of-treatment values; least squares mean and SE are reported for changes from baseline; least squares mean is reported for percent changes from baseline vs. placebo*AA* arachidonic acid, *DHA* docosahexaenoic acid, *DPA* docosapentaenoic acid, *EPA* eicosapentaenoic acid, *IPE* icosapent ethyl, *RBC* red blood cell, *SD* standard deviation, *SE* standard error

Compared with placebo, icosapent ethyl 4 g/day resulted in substantial and statistically significant mean percent increases in total omega-3 fatty acid concentrations in plasma (142.22%) and RBCs (89.38%; all *P *\< 0.0001; Table [3](#Tab3){ref-type="table"}), and smaller, but significant decreases in total omega-6 fatty acid and monounsaturated fatty acid concentrations (all *P *\< 0.05). A slight increase in saturated fatty acids was observed in RBCs (3.13%; *P *= 0.0011) in the icosapent ethyl 4 g/day group versus placebo, with no significant change in plasma (Table [3](#Tab3){ref-type="table"}).Table 3Percent change in the proportion of fatty acid classes to total fatty acidsFatty acid class^a^IPE 4 g/dayPlaceboChange from baseline, IPE 4 g/day vs placebo, %, *P*Proportion of total, %^b^Baseline (SD)Week 12 (SD)Change (SE)Baseline (SD)Week 12 (SD)Change (SE)**Plasma**Saturated33.7933.59− 0.5434.2033.63− 0.690.48*n* = 50, 53(2.543)(2.389)(0.312)(2.488)(2.357)(0.297)0.6611Monounsaturated28.6326.72− 2.0428.6728.40− 0.38− 5.58*n* = 50, 53(2.770)(2.976)(0.442)(2.586)(3.301)(0.421)0.0038Total n-32.957.164.453.113.120.25142.22*n* = 50, 53(0.479)(1.978)(0.194)(1.297)(1.136)(0.185)\< 0.0001Total n-634.6332.54− 1.8534.0234.850.79− 7.66*n* = 50, 53(3.910)(3.429)(0.520)(3.350)(3.840)(0.494)\< 0.0001**RBC membranes**Saturated43.3544.150.4743.8242.98− 0.883.13*n* = 50, 53(2.165)(3.010)(0.342)(2.594)(1.724)(0.326)0.0011Monounsaturated20.4319.79− 0.4619.8920.030.05− 2.65*n* = 50, 53(2.199)(1.688)(0.227)(1.587)(1.848)(0.215)0.0401Total n-35.4610.224.935.725.52− 0.0189.38*n *= 50, 53(1.130)(2.484)(0.242)(1.185)(1.116)(0.231)\< 0.0001Total n-630.7525.84− 4.9130.5831.470.81− 19.60*n* = 50, 53(1.967)(3.165)(0.365)(3.051)(2.178)(0.348)\< 0.0001^a^Patient numbers (*n*) are reported for icosapent ethyl 4 g/day and placebo, respectively^b^Proportion of total where total = sum of omega-3, omega-6, monounsaturated, and saturated fatty acidsMean and SD are reported for baseline and end-of-treatment values; least squares mean and SE are reported for changes from baseline; least squares mean is reported for percent changes from baseline vs. placeboSaturated fatty acids: sum of myristic, palmitic, stearic, arachidic, behenic, and lignoceric acidsMonounsaturated fatty acids: myristoleic, palmitoleic,*cis*-vaccenic, oleic, gondoic/gadoleic, erucic, and nervonic acidsn-6 fatty acids: sum of linoleic, γ-linolenic, eicosadienoic, dihomo-γ-linolenic, n-6 arachidonic, adrenic, and n-6 docosapentaenoic acidsn-3 fatty acids: sum of α-linolenic, stearidonic, eicosatrienoic, n-3 arachidonic, eicosapentaenoic, n-3 docosapentaenoic, and docosahexaenoic acids*IPE* icosapent ethyl, *RBC* red blood cell, *SD* standard deviation, *SE* standard error

These fatty acids described above, together with four additional fatty acids found in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} (palmitic, C16:0; stearic, C18:0; oleic, C18:1n-9; and linoleic acids, C18:2n-6), are either the most abundant in terms of mass contribution to the total lipid concentration (and thus major sources of energy) or they are less abundant but have important physiological characteristics, even at low concentrations relative to the abundant fatty acids. In plasma, significant reductions were observed in palmitic, stearic, oleic, and linoleic acids compared with placebo (Table [1](#Tab1){ref-type="table"}; all *P *\< 0.001); in RBCs, reductions were observed in all four of these fatty acids compared with placebo, but were only significant for linoleic acid (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec5}
==========

In this prespecified exploratory subset analysis of data from the 12-week, double-blind ANCHOR study, icosapent ethyl 4 g/day, a high-purity prescription form of the ethyl ester of EPA, significantly increased concentrations of EPA and DPA (a metabolite of EPA) in plasma and RBCs compared with placebo in patients with high cardiovascular risk and high TG concentrations while receiving statin therapy to control Ldl-C. Studies suggest that these two omega-3 fatty acids confer distinct and complementary cardiovascular benefits \[[@CR20]\]. An increase in plasma EPA concentrations with icosapent ethyl is dose-dependent, as is its TG-lowering effect \[[@CR21]\]. Compared with placebo, icosapent ethyl significantly decreased the concentration of AA, the AA/EPA ratio, and total omega-6 fatty acid concentrations and significantly increased the total omega-3 fatty acid concentrations in plasma and RBCs accordingly. As with previous investigations of EPA-only treatment, icosapent ethyl did not significantly increase DHA concentrations in plasma in the current analysis, indicating that previously reported TG lowering and changes in fatty acids were due to increases in EPA levels but not DHA levels \[[@CR1], [@CR13], [@CR21]--[@CR23]\].

Icosapent ethyl had similar effects on plasma and RBC fatty acid levels in an analogous prespecified exploratory subset analysis of the MARINE study, indicating consistency across two patient populations. In the MARINE study, icosapent ethyl 4 g/day increased plasma concentrations of EPA by 792%, DPA by 151%, and the ratio of omega-3/omega-6 fatty acids by 146% while decreasing AA by 27% and the AA/EPA ratio by 99% compared with placebo (all *P *\< 0.0001) \[[@CR13]\]. In RBCs, icosapent ethyl 4 g/day increased EPA by 490%, DPA by 106%, and the omega-3/omega-6 fatty acid ratio by 107% and decreased AA by 16% and the AA/EPA ratio by 102% (all *P *\< 0.0001) compared with placebo. No significant changes in DHA concentrations were observed in plasma or RBCs.

Similar results were found in relative changes in plasma EPA levels in ANCHOR using liquid chromatography-tandem mass spectrometry (LC--MS/MS), another established fatty acid analysis method \[[@CR21]\]. By LC--MS/MS, after 12 weeks of treatment with icosapent ethyl 4 g/day, EPA increased from a mean (SD) baseline level of 28.1 (18.8) μg/ml to 182.6 (71.7) μg/ml in plasma and from 11.6 (5.6) μg/ml to 72.7 (31.5) μg/ml in RBCs.

Using bioanalytical methods similar to those used in the current analysis, a supplemental analysis of data from 15,534 patients from the Japan EPA Lipid Intervention Study (JELIS) also found significant increases in plasma levels of EPA and DPA, significant decreases in plasma levels of AA, and no increase in plasma levels of DHA with EPA ethyl ester 1.8 g/day \[[@CR1]\]. The main finding of JELIS, conducted in Japanese patients receiving guideline-driven statin therapy (*N* = 18,645), was a 19% reduction in a composite endpoint of major coronary events with EPA treatment versus statin therapy alone \[[@CR24]\]. The analysis of fatty acid plasma levels in the JELIS patients demonstrated that in the EPA group, a high plasma EPA concentration was significantly associated with a lower risk of a major coronary event but no significant association was found for the other plasma fatty acid levels investigated \[[@CR1]\].

The potential cardiovascular benefits of icosapent ethyl 4 g/day have recently been evaluated in the Reduction of Cardiovascular Events with Icosapent Ethyl--Intervention Trial (REDUCE-IT; NCT01492361), which was focused on a multinational, high-risk, statin-treated patient population similar in background risk and statin therapy to that in the ANCHOR study \[[@CR25]\]. Patients (*N* = 8179) on stable statin therapy had Ldl-C controlled to between 41 and 100 mg/dl, elevated TG between 135 and 499 mg/dl, and either established cardiovascular disease (secondary prevention cohort) or diabetes and at least one other cardiovascular risk factor (primary prevention cohort) \[[@CR25]\]. The primary composite endpoint was time to first occurrence of a major adverse cardiovascular event (MACE) that included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. The key secondary endpoint was the first occurrence of three-point MACE consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. REDUCE-IT demonstrated a statistically significant relative risk reduction of 25% \[hazard ratio (HR), 0.75; 95% confidence interval (CI), 0.68--0.83; *P *\< 0.001\] for icosapent ethyl versus placebo in the primary composite endpoint and a relative risk reduction of 26% (HR, 0.74; 95% CI, 0.65--0.83; *P *\< 0.001) in the key secondary composite endpoint over a median follow-up of 4.9 years \[[@CR25]\]. In REDUCE-IT, EPA was measured in serum using an LC--MS/MS method similar to that used in ANCHOR \[[@CR21]\], with large increases in EPA, as observed in the ANCHOR plasma results presented herein \[[@CR25]\]. Plasma EPA levels achieved in the JELIS trial were also substantially high, and JELIS also demonstrated a statistically significant reduction in cardiovascular events as discussed earlier.

The findings in this study are limited to an FDA-approved prescription formulation of EPA (icosapent ethyl) and cannot be extrapolated to other prescription omega-3 formulations containing different concentrations of DHA or other omega-3 fatty acids, or to dietary supplements, which are unregulated and contain much lower concentrations of EPA, DHA, or other fatty acids \[[@CR26]\]. DHA may increase Ldl-C levels in some patients \[[@CR27]\], and outcomes studies of low-dose omega-3 fatty acid dietary supplements have not found any cardiovascular benefit \[[@CR28]\].

Icosapent ethyl is not currently FDA approved to reduce the risk of MACE, but further assessment of REDUCE-IT data will help to provide a greater understanding of the REDUCE-IT results, their place in clinical treatment, and the potential implications for fatty acid profiles and cardiovascular outcomes following icosapent ethyl treatment.

Physiologically, potential beneficial effects of omega-3 fatty acids include reducing inflammatory processes, such as those associated with cardiovascular disease, whereas omega-6 fatty acids are associated with proinflammatory effects \[[@CR6], [@CR7], [@CR29], [@CR30]\]. EPA competitively inhibits AA as a substrate in the production of eicosanoids and produces molecules that exert anti-inflammatory and/or antithrombotic effects \[[@CR6], [@CR7], [@CR29]\]. The EPA/AA ratio is correlated to the progression of arteriosclerotic disease and cardiovascular outcomes \[[@CR1], [@CR7], [@CR31], [@CR32]\]. In the current analysis, icosapent ethyl significantly increased total omega-3 fatty acid concentrations and reduced the content of AA in both plasma and RBCs, significantly decreasing the AA/EPA ratio.

These potentially beneficial anti-inflammatory effects of icosapent ethyl versus placebo on plasma and RBC fatty acids are consistent with the previously reported reductions in markers of inflammation and oxidation in patients in the ANCHOR study, including high sensitivity C-reactive protein, lipoprotein-associated phospholipase A~2~, and oxidized LDL \[[@CR16]\].

Limitations of the current analysis of plasma fatty acid levels include small sample size relative to the entire ANCHOR population, within-subject variability \[[@CR33]\], and that changes in plasma lipid levels affect plasma fatty acid levels; thus, lipid-lowering agents such as icosapent ethyl are expected to affect fatty acid levels. The analysis of RBC fatty acid levels in this study, however, offers additional understanding of the effects of icosapent ethyl, as RBCs are more reflective of the levels of EPA and other fatty acids in tissues compared with levels in plasma, and the concentrations of both EPA and DHA are known to be less variable in RBCs than in plasma \[[@CR33]\]. Furthermore, the levels of EPA, DPA, and DHA in RBCs have been linked with cardiovascular risk, and thus analyses of RBC fatty acid levels offer additional insight into potential beneficial effects of omega-3 therapies. RBC levels of EPA and DPA help predict risk of 2-year mortality in myocardial infarction patients, and in an observational study, dietary intake and RBC levels of EPA and DHA were inversely related to the risk of primary cardiac arrest \[[@CR2], [@CR34]\]. However, it should be noted that in the current analysis, RBC fatty acid levels may have been limited by the 12-week study duration. While EPA concentration in RBC membranes may double as early as 3 days after supplementation, the lifespan of RBCs is approximately 120 days in adult humans \[[@CR35]\]. Finally, as current guidelines favor as-high-as-tolerable statin intensity, it may be worth noting that in the overall ANCHOR population, approximately 90% of patients were on moderate- to high-intensity statin regimens.

Conclusions {#Sec6}
===========

Icosapent ethyl 4 g/day significantly increased plasma and RBC EPA concentrations and caused other potentially beneficial shifts in fatty acid plasma and RBC membrane content versus placebo.
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